Skip to main content

Table 3 Responses on the management of the inflammatory arthritis in patient with a 6-week unplanned pregnancy with conventional synthetic disease modifying anti-rheumatic drugs, biologics/small molecules, and other medications

From: Management of Inflammatory Arthritis in pregnancy: a National Cross-Sectional Survey of Canadian rheumatologists

 

Continue drug, continue pregnancy (%)

Stop drug, continue pregnancy (%)

Continue drug, counsel regarding termination (%)

Stop drug, counsel regarding termination (%)

Not sure (%)

Conventional synthetic disease modifying anti-rheumatic drugs

 Azathioprine

80.3*

6.1

1.5

4.5

7.6

 Chloroquine

71.2

7.6

3.0

0

18.2

 Cyclophosphamide

0

16.7

13.6

60.6

9.1

 Cyclosporine

27.3

18.2

1.5

19.7

33.3

 Doxycycline

0

29.2

0

6.2

64.6

 Gold salts

30.3

18.2

0

9.1

42.4

 Hydroxychloroquine

90.9*

4.5

1.5

0

3.0

 Leflunomide

0

16.7

6.1

69.7

7.6

 Methotrexate

0

22.7

7.6

65.2

4.5

 Minocycline

0

34.8

0

6.1

69.7

 Mycophenolate mofetil

3.0

19.7

10.6

47.0

19.7

 Sulfasalazine

76.6*

14.1

0

1.6

7.8

Biologics/small molecules

 Abatacept

24.2

45.5

1.5

6.1

22.7

 Adalimumab

66.7

25.8

1.5

1.5

4.5

 Anakinra

15.2

39.4

1.5

4.5

39.4

 Apremilast

4.6

35.4

0

6.2

53.8

 Certolizumab

63.1

26.2

1.5

0

9.2

 Etanercept

69.7

24.2

0

1.5

4.5

 Golimumab

60.6

28.8

1.5

1.5

7.6

 Infliximab

60.0

29.2

1.5

1.5

7.7

 Rituximab

18.2

39.4

1.5

6.1

34.8

 Tocilizumab

18.2

39.4

1.5

4.5

36.4

 Tofacitinib

3.0

31.8

0

7.6

57.6

 Ustekinumab

13.8

33.8

1.5

4.6

46.2

Other medications

 Celecoxib

39

56

0

0

3

 Ibuprofen

64

33

0

0

3

 Naproxen

65

32

0

0

3

 Prednisone

85*

12

0

0

3

  1. *Indicates consensus among respondents based on a priori cut-off of ≥75%